期刊文献+

COX-2和HER-2在食管鳞癌组织中的表达及相关性研究 被引量:5

Expression and clinical significance of COX-2 and HER-2 in esophageal squamous cell carcinoma
下载PDF
导出
摘要 目的研究COX-2和HER-2在食管鳞癌(ESCC)组织中的表达及与临床病理特征之间关系。方法采用免疫组织化学方法检测519例食管鳞癌组织中COX-2和HER-2的表达水平,分析两者与临床病理特征之间的关系以及两者之间的相关性。结果 COX-2阳性表达率为411/519(79.2%),COX-2的表达与食管鳞癌分期?分化程度?肿块直径大小,淋巴结转移均无相关性(P>0.05);HER-2阳性表达率为120/519(23.1%),与食管鳞癌分化程度、淋巴结转移数目呈正相关(P<0.05);而与食管癌分期?肿块直径大小无相关性(P>0.05)。HER-2的表达与COX-2的表达之间正相关(r=0.151,P=0.01)。结论 HER-2蛋白与COX-2蛋白在食管鳞状细胞癌中均有不同程度的表达,COX-2可能是食管鳞状细胞癌发生的早期事件;HER-2蛋白过表达可能是食管癌预后不良的一个指标;COX-2在食管鳞状细胞癌中高水平表达且与HER-2密切相关,提示食管鳞状细胞癌中COX-2和HER-2存在相互作用机制并共同促进肿瘤的发生及发展。 Aim To investigate the expression and correlation of cyclooxygenase-2 and HER-2 oncogene in esophageal squamous cell carcinoma.Methods cyclooxygenase-2 protein and HER-2 oncogene expression in 519 cases of esophageal squamous cell carcinoma were detected by immunochemical staining and the relationship between COX-2 and HER-2 was analyzed together with the clinicopathologic characteristics.Results 411 cases of 519(79.2%)esophageal squamous cell carcinoma samples were positive for cyclooxygenase-2.Overexpression of cyclooxygenase-2 was not associated with TNM stage,histological grade,lymph node metastasis and the size of tumor(P0.05).120 cases of 519(23.1%)esophageal squamous cell carcinoma specimens were positive for HER-2,which correlated with the factors of histologic grade and lymph node metastasis(P0.05),while not related with TNM stage,the size of tumor.The expression of HER-2 was closely correlated with the expression of COX-2(P0.05).Conclusion Both COX-2 and HER-2 overexpress in ESCC.COX-2 seems to be an early event in the development of ESCC.HER-2 may play independent prognosis target rule.The expression of COX-2 is significantly related to the expression of HER-2,which indicates that HER-2 and COX-2 can regulate each other and induce the tumorgenesis and development together.
出处 《安徽医药》 CAS 2011年第7期874-876,共3页 Anhui Medical and Pharmaceutical Journal
关键词 食管肿瘤 环加氧酶-2 HER-2 免疫组织化学 esophageal neoplasms COX-2 HER-2 immunohistochemistry
  • 相关文献

参考文献12

  • 1徐天亮,孙国平,刘虎,秦涛,焦洋,彭万仁,潘跃银,熊福星,顾康生,陈振东.奈达铂联合5-氟脲嘧啶治疗顺铂耐药的晚期食管癌临床疗效观察[J].安徽医药,2009,13(8):965-967. 被引量:8
  • 2王顺文,高青.环氧化酶-2与食管癌临床病理特征及预后关系的研究[J].肿瘤防治杂志,2004,11(10):1051-1053. 被引量:6
  • 3Buskens C J, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase-2 expression in patients with adenocarcino- ma of the esophagus [ J ]. Gastroenterology, 2002,122 ( 7 ) : 1800 - 7.
  • 4Shamma A, Yamamoto H. Up-regulation of cyclooxygenase-2 in squ amous carcinogenesis of the esophagus [ J ]. Clin Cancer Res,2000, 6(4) :1229 -38.
  • 5Koppert LB, Wen W, Dekken HW, et al. The Molecular Biology of Esophageal Adenocarcinoma [ J ]. Journal of Surgical Oncology, 2005,92 ( 1 ) : 169 - 90.
  • 6Johnson RC,Rieci A Jr, Cartun RW,et al. p185 HER-2 overexpres- sion in human breast cancer using molecular and immunohistochemi- cal methods [ J ]. Cancer Invest,2000,18 (4) : 336 - 41.
  • 7Linderholm BK,Lindh B, Tavelin B, et al. P53 and vascular-endo- thelial-growth-factor (VEGF)expression predicts outcome in 833 patients with primary breast carcinoma [ J]. lnt J Cancer, 2000,89 (1) :51 -9.
  • 8Linderholm BK, Lindahl T, Holmberg L, et al. The expression of" vas- cular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer [ J 1. Cancer Res,2001,61 (5) : 2256 - 67.
  • 9Lebeau A,Deimling D, Kaltz C, et al. Her-2 /neu analysis in archi- val tissue samples of human breast cancer:comparison of immuno- histochemistry and fluorescence in situ hybridization [ J ]. Clin On- col,2001,19(2) :354 -561.
  • 10Kotha S, Larry N, William G, et al. Cyclooxygenase-2 is overex- pressed ira Her-2/neu-positive breast cancer [ J ]. Biol Chem,2002, 277(21 ) :18649 -57.

二级参考文献35

  • 1彭万仁,宛新安,孙国平,杨震,李娜.丹皮酚协同顺铂抑制人食管癌Eca-109细胞的增殖[J].安徽医药,2007,11(6):492-493. 被引量:6
  • 2郝吉庆,钱勇,笪洁.奈达铂治疗中晚期食管癌41例临床分析[J].安徽医药,2007,11(6):499-500. 被引量:4
  • 3Wu XX, Kakehi Y. Enhancement of lexatumumab - induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner[J]. Clin Cancer Res,2009,15(6) :2039 -47.
  • 4Fruehauf JP, Brem H, Brem S, et al. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas [ J ]. Clin Cancer Res, 2006,12 ( 15 ) :4523 - 32.
  • 5Mognowska M, Surowiak P, Nowak-Markwitz E, et al. Analysis of hMLH1 and hMSH2 expression in eisplatin -treated ovarian cancer patients [ J ]. Ginekol Pol,2008,79 (12) :826 - 34.
  • 6Mozzetti S, Iantomasi R, De Maria I, et al. Molecular mechanisms of patupilone resistance[J]. Cancer Res,2008,68(24) :10197 -204.
  • 7Akaza H, Saijo N, Aiha K, et al. Platinum compounds in cancer therapy past, present, and future [ J ]. Gan To Kagaku Ryoho,2001, 28(5) :625 -35.
  • 8Obira M, Yamashita Y, Matsumura Y, et al. Chemoradiation therapy for esophageal cancer[ J]. Gan To Kagaku Ryoho, 2002,29 (5) : 695 - 702.
  • 9Yoshioka T, Gamoh M, Shineha R, et al. A new combination chemotherapy with cis-diammins-glycolatoplatinum (Nedaplatin) and 5 - fluorouracil for advanced esophageal cancers [ J ]. Intern Med, 1999, 38(11) :844 -8.
  • 10张丰林.长春瑞滨联合顺铂、亚叶酸钙/5-氟脲嘧啶治疗晚期食管癌21例[J].安徽医药,2007,11(8):691-692. 被引量:5

共引文献17

同被引文献41

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部